BioSpace News Archive

Astellas Pharma Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI.

Xenetic Biosciences, Inc. today reported its financial results for the year ended December 31, 2023.

Brain–computer interface company Precision Neuroscience Corporation announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces complete clinical response in three patients with serious invasive fusarium infection following treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B.

GE HealthCare will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.

RedDrop Dx, Inc., Innosphere Ventures Client Company, is pleased to announce that its innovative blood collection device, RedDrop One, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for prescription use.

MorphoSys AG announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the proposed acquisition of MorphoSys by Novartis AG, following the expiration of the HSR Act waiting period.

ANGLE plc is pleased to announce its participation at the 14th European Breast Cancer Conference being held in Milan, Italy on 20 to 22 March 2024.

Molecure S.A. has started the clinical trial where OATD-01 is being administered to patients with active pulmonary sarcoidosis as part of a Phase II clinical trial.